SCHEMBL5205524

SCHEMBL5205524

CC(C)(C)[Si](C)(C)OCc1cccc(CNC(=O)c2cccc(CCCl)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.46
MMP13 P45452 2/20 0.46
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HPGD P15428 3/20 0.45
MAPT P10636 2/20 0.45
HTT P42858 2/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALOX12 P18054 1/20 0.45
CYP2C9 P11712 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
TP53 P04637 2/20 0.44
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8320447 0.75 LOXL2 (0.56) NPC1RAB9ASMN1; SMN2HPGDMAPT
SCHEMBL5341608 0.75 MRGPRX4 (0.52) RAB9ASMN1; SMN2ALDH1A1NPSR1TP53
SCHEMBL12095859 0.73 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2HPGDMAPT
SCHEMBL5871245 0.72 CYP4F2 (0.43) MAPTALDH1A1TDP1
SCHEMBL5205530 0.72 NR1H4 (0.43) NR1H4MMP13NPC1RAB9ASMN1; SMN2
SCHEMBL15687564 0.72 IDO1 (0.36) CYP3A4
SCHEMBL863463 0.71 F10 (0.36) RAB9ASMN1; SMN2TP53MRGPRX4
SCHEMBL31393761 0.71 F10 (0.36) RAB9ASMN1; SMN2TP53MRGPRX4
SCHEMBL10204501 0.71 MRGPRX4 (0.38) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6156231 0.71 MAOB (0.41) KMT2AMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1304324-B1 SEROTONIN REUPTAKE INHIBITORS DAINIPPON SUMITOMO PHARMA CO (JP) 2007-10-03 EP disclosed
US-6787560-B2 PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-09-07 US disclosed
US-20030191126-A1 Psychological disorders; antidepressants SUMITOMO PHARMACEUTICALS COMPANY LIMITED 2003-10-09 US disclosed
EP-1304324-A1 SEROTONIN REUPTAKE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191126-A1 Psychological disorders; antidepressants CRH, HTR2C, HTR1A NR1H4 1169/4885MMP13 4263/4885NPC1 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.